[Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer].
OBJECTIVE
Studies suggest that hypoxia-inducible factor 1α (HIF-1α) expression favours expression of vascular endothelial growth factor A (VEGF-A) involving cellular proliferation, angiogenesis, and metastasis in different cancers including lung cancer. We investigated the correlation of HIF-1α and VEGF-A with clinicopathologic parameters and clinical outcomes in surgically resected non-small cell lung cancer patients.


METHODS
Prospective study to analyze the expression of VEGF-A and HIF-1α with real time-polymerase chain reaction in 66 patients operated on non-small cell lung cancer.


RESULTS
Mean age was 62.7±9.8 and male:female ratio was 7.3:1. According to the new 2009 TNM classification, stage i, ii, and iii included 27 (40.9%), 21 (31.8%) and 18 (27.3%) patients, respectively. Histological subtypes were: 47% squamous cell carcinoma, 33.3% adenocarcinoma, and 19.7% others. Mean follow-up time was 42.3 months. Median survival was 43.2 months and 5-year overall survival was 42.4%. There was no correlation between HIF-1α and VEGF-A (P=.306). The overexpression of VEGF-A was found more frequent in advanced stage and in lymph nodes metastasis (P=.034 and P=.059, respectively). In multivariate analysis, T descriptor and VEGF-A overexpression were independent prognostic factors (odds ratio [OR]=2.37, P=.016, and OR=2.51, P=.008, respectively). HIF-1α overexpression showed an OR=0.540, but without statistical significance (P=.172).


CONCLUSIONS
The present study revealed that VEGF-A overexpression was an adverse independent prognostic factor. On the contrary, HIF-1α overexpression showed a tendency to a protective effect on survival of surgically treated non-small cell lung cancer patients, although without statistical significance.
Servicio de Cirugía Torácica, Hospital General Universitario de Albacete, Albacete, España. Electronic address: tonyhonguero@yahoo.es.
Antonio Francisco
AF
Honguero Martínez
Servicio de Cirugía Torácica, Hospital General Universitario de Valencia, Valencia, España.
Antonio
A
Arnau Obrer
Servicio de Cirugía Torácica, Hospital General Universitario de Valencia, Valencia, España.
Santiago
S
Figueroa Almazán
Servicio de Cirugía Torácica, Hospital General Universitario de Valencia, Valencia, España.
Néstor
N
Martínez Hernández
Servicio de Cirugía Torácica, Hospital General Universitario de Valencia, Valencia, España.
Ricardo
R
Guijarro Jorge
D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011013:Pneumonectomy; D011379:Prognosis; D011446:Prospective Studies; D060888:Real-Time Polymerase Chain Reaction; D015996:Survival Rate; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D014408:Biomarkers, Tumor; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A
Cirugía; Cáncer de pulmón no microcítico; Factor de crecimiento endotelial vascular A; Factor inducible por la hipoxia 1-α; Hypoxia-inducible factor 1-α; Non-small cell lung cancer; Supervivencia; Surgery; Survival; Vascular endothelial growth factor A